MX2022009044A - Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina. - Google Patents

Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina.

Info

Publication number
MX2022009044A
MX2022009044A MX2022009044A MX2022009044A MX2022009044A MX 2022009044 A MX2022009044 A MX 2022009044A MX 2022009044 A MX2022009044 A MX 2022009044A MX 2022009044 A MX2022009044 A MX 2022009044A MX 2022009044 A MX2022009044 A MX 2022009044A
Authority
MX
Mexico
Prior art keywords
drug conjugate
eribulin
derivative
medicine
preparation
Prior art date
Application number
MX2022009044A
Other languages
English (en)
Inventor
Qiyue Hu
Jian Huang
Xiuzhao Yu
Jindong Liang
Bo Zhu
Mi Tang
Lingjian Zhu
Xing Sun
Yang Yang
Wenming Ren
Original Assignee
Shanghai Senhui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Senhui Medicine Co Ltd filed Critical Shanghai Senhui Medicine Co Ltd
Publication of MX2022009044A publication Critical patent/MX2022009044A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente INVENCIÓN se refiere a un conjugado de fármaco de un derivado de eribulina, por lo tanto, a un método de preparación ya una aplicación del mismo en medicina. Específicamente, se proporciona un conjugado de anticuerpo y fármaco que contiene una porción de fármaco derivado de eribulina. La presente invención se refiere además a un método para tratar el cáncer mediante la administración del conjugado de anticuerpo-fármaco proporcionado en el presente documento.
MX2022009044A 2020-01-22 2021-01-22 Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina. MX2022009044A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010073671 2020-01-22
CN202010114980 2020-02-25
CN202011153368 2020-10-26
PCT/CN2021/073314 WO2021148003A1 (zh) 2020-01-22 2021-01-22 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2022009044A true MX2022009044A (es) 2022-08-11

Family

ID=76992064

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009044A MX2022009044A (es) 2020-01-22 2021-01-22 Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina.

Country Status (10)

Country Link
US (1) US20230144203A1 (es)
EP (1) EP4094779A4 (es)
JP (1) JP2023511163A (es)
KR (1) KR20220130160A (es)
AU (1) AU2021210079A1 (es)
BR (1) BR112022014398A2 (es)
CA (1) CA3168654A1 (es)
MX (1) MX2022009044A (es)
TW (1) TW202140078A (es)
WO (1) WO2021148003A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11998544B2 (en) 2018-06-01 2024-06-04 Eisai R&D Management Co., Ltd. Methods of using splicing modulators
KR20220095197A (ko) 2019-11-07 2022-07-06 에자이 알앤드디 매니지먼트 가부시키가이샤 항-메소텔린 에리불린 항체-약물 컨쥬게이트 및 이용 방법
WO2023024949A1 (zh) * 2021-08-24 2023-03-02 昆山新蕴达生物科技有限公司 一种由可断裂连接子偶联的抗体偶联药物
CN115957339A (zh) * 2021-09-16 2023-04-14 正大天晴药业集团股份有限公司 抗体药物偶联物及其组合物和用途
TW202317088A (zh) * 2021-10-14 2023-05-01 大陸商江蘇恒瑞醫藥股份有限公司 艾日布林衍生物的製備方法
WO2023098691A1 (zh) * 2021-12-01 2023-06-08 上海生物制品研究所有限责任公司 抗体药物偶联物及其用途
WO2023103854A1 (zh) * 2021-12-09 2023-06-15 昆山新蕴达生物科技有限公司 一种亲和力改善的抗体-药物偶联物、其制备方法及应用
WO2023124963A1 (zh) * 2021-12-27 2023-07-06 昆山新蕴达生物科技有限公司 一种可逆反应减少的抗体-药物偶联物，其制备方法及应用
TW202334207A (zh) * 2022-01-26 2023-09-01 大陸商上海邁晉生物醫藥科技有限公司 一種包含抗ｃｄ７９ｂ抗體藥物偶聯物的醫藥組成物及其用途
WO2023143320A1 (zh) * 2022-01-28 2023-08-03 博瑞生物医药（苏州）股份有限公司 用于制备抗体药物偶联物的连接子、化合物及用途
WO2023143319A1 (zh) * 2022-01-28 2023-08-03 启德医药科技（苏州）有限公司 抗体药物偶联物、药物组合物及用途
WO2023143351A1 (zh) * 2022-01-29 2023-08-03 上海盛迪医药有限公司 糖皮质激素的药物偶联物
WO2023155808A1 (zh) * 2022-02-16 2023-08-24 苏州宜联生物医药有限公司 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
WO2024078612A1 (en) * 2022-10-14 2024-04-18 Genequantum Healthcare (Suzhou) Co., Ltd. Linker-payload compound, conjugates and applications thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
WO1999065894A1 (en) * 1998-06-17 1999-12-23 Eisai Co., Ltd. Macrocyclic analogs and methods of their use and preparation
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
AU2003209447B8 (en) 2002-03-01 2008-10-23 Immunomedics, Inc. RS7 antibodies
AU2003263964C1 (en) 2002-07-31 2010-08-19 Seagen Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
SI1725249T1 (sl) 2003-11-06 2014-04-30 Seattle Genetics, Inc. Spojine monometilvalina, sposobne konjugacije na ligande
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
US8257706B2 (en) 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
CN103201291B (zh) * 2010-11-10 2015-12-09 日本化药株式会社 抗单链iv型胶原多肽抗体和包含其的用于诊断、预防或***的药物或药剂
US9156825B2 (en) 2012-01-13 2015-10-13 The General Hospital Corporation Anesthetic compounds and related methods of use
AR091701A1 (es) * 2012-07-09 2015-02-25 Genentech Inc Anticuerpos anti-cd22 e inmunoconjugados
CN104411337A (zh) * 2012-07-09 2015-03-11 基因泰克公司 包含抗cd79b抗体的免疫偶联物
MA37840B1 (fr) * 2012-07-09 2020-05-29 Genentech Inc Immunoconjugués comprenant des anticorps anti-cd79b
KR102087017B1 (ko) 2012-10-11 2020-03-10 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
BR112017011326A2 (pt) * 2014-12-05 2018-07-31 Genentech, Inc. anticorpo, ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo, imunoconjugado, composição farmacêutica, usos do anticorpo, métodos para tratar ou retardar a progressão de distúrbio proliferativo celular e para intensificar a função imune
SG10202007520WA (en) 2016-03-02 2020-09-29 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
CN109475567A (zh) * 2016-06-09 2019-03-15 布兰克生物股份有限公司 基于硅烷醇的治疗有效载荷
WO2018217894A1 (en) * 2017-05-24 2018-11-29 Eisai R&D Management Co., Ltd. Fluorine-labelled halichondrin derivatives and related methods of synthesis
CN107488230B (zh) * 2017-09-01 2019-01-18 浙江大学 一种抗人CD79a胞外端蛋白的抗体、编码基因及应用
CN113683622A (zh) * 2017-12-15 2021-11-23 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
MX2021003382A (es) 2018-09-26 2021-05-27 Jiangsu Hengrui Medicine Co Conjugado de ligando y farmaco analogo de exatecan, metodo de preparacion del mismo y aplicacion del mismo.

Also Published As

Publication number Publication date
JP2023511163A (ja) 2023-03-16
AU2021210079A1 (en) 2022-08-25
BR112022014398A2 (pt) 2022-09-13
EP4094779A1 (en) 2022-11-30
EP4094779A4 (en) 2023-11-22
US20230144203A1 (en) 2023-05-11
TW202140078A (zh) 2021-11-01
KR20220130160A (ko) 2022-09-26
CN114845739A (zh) 2022-08-02
WO2021148003A1 (zh) 2021-07-29
CA3168654A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
MX2022009044A (es) Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina.
EP4223316A3 (en) Improved antibody-oligonucleotide conjugate
WO2020236825A3 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2019199861A3 (en) Hemp extract for treatment of pain in animals
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
MX2023001163A (es) Conjugado de farmaco anticuerpo anti-cd79b, metodo de preparacion y uso farmaceutico del mismo.
NZ621433A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
CR10244A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
IN2012DN02826A (es)
NZ595767A (en) Composition for the treatment of prostate cancer
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
MX2023013890A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
MX2023001648A (es) Conjugado de anticuerpo y farmaco.
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
MX2022009597A (es) Conjugado de anticuerpo-farmaco que incluye derivado de dinucleotido ciclico novedoso.
MX2020009842A (es) Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido.
MX2023005192A (es) Composicion que comprende una combinacion de inhibidor de punto de control inmunitario y conjugado de anticuerpo-amatoxina para uso en la terapia del cancer.
BRPI0508983A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano
MX2023000868A (es) Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo.
ZA202308034B (en) Interferon-based cancer treatment method, and pharmaceutical combination
ZA202308033B (en) Method and pharmaceutical combination for preventing cancer recurrence
MX2022012001A (es) Tratamiento preventivo de la migra?a.
CA3199014A1 (en) Combination therapy for the treatment of a liver disease